Phaseline

Targets › GPC3

GPC3 (Glypican-3): drug programs, companies and trials

19 programs from 16 companies in 21 trials: 20 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Cell surface proteoglycan. Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). (UniProt, P51654)

Open in Phaseline: the race on GPC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Newish Technology (Beijing)NWRD06
Glypican 3 (GPC3)-targeted DNA plasmid vaccine
GPC3Phase 2Hepatocellular Carcinoma (HCC)Dec 2028
National Cancer Institute (NCI)anti-GPC3 CAR-T cells
anti-GPC3 chimeric antigen receptor (CAR) T-cell therapy
GPC3Phase 1Hepatocellular CarcinomaDec 2026
BeOne MedicinesBGB-B2033
Anti-glypican-3 (GPC3) antibody
GPC3Phase 1Metastatic Hepatocellular CarcinomaMar 2027
Keymed Biosciences Co.LtdCM350
anti-GPC3 antibody
GPC3Phase 1Advanced Solid TumorApr 2027
Memorial Sloan Kettering Cancer CenterCodrituzumab
anti-GPC3 monoclonal antibody
GPC3Phase 1Primary Extra-cranial Solid TumorJun 2027
AstraZenecaAZD9793
T cell-engaging antibody targeting GPC3 on tumour cells
GPC3Phase 1Hepatocellular CarcinomaJun 2027
Zhejiang UniversityCBG166
anti-GPC3 CAR-T cell therapy
GPC3Phase 1Advanced Hepatocellular CarcinomaJul 2027
Baylor College of MedicineCARE T cells (15.21.GPC3-CAR T cells)
Glypican-3-specific CAR T cells expressing interleukin-15 and interleukin-21
GPC3, GPCSPhase 1Liver Cancer; Hepatoblastoma; Glioblastoma Multiforme of BrainAug 2027
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB6426 for Injection
anti-GPC3 antibody-drug conjugate
GPC3Phase 1Advanced MalignanciesAug 2027
Zymeworks BCZW251
anti-GPC3 antibody-drug conjugate
GPC3Phase 1Hepatocellular CarcinomaSep 2027
Aptamer SciencesAST-201
GPC3-targeting aptamer
GPC3Phase 1NeoplasmsDec 2027
Eastern Hepatobiliary Surgery HospitalSuper Hi-TCR-T cells
Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP
PVRL4, KLRC1, TROP2, B7H3, GPC3Phase 1Advanced Hepatocellular Carcinoma (HCC)Jan 2028
Second Affiliated Hospital of Guangzhou Medical UniversityMesothelin/GPC3/GUCY2C-CAR-T cells
CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1
MSLN, GPC3, GUCY2CPhase 1Pancreas CancerMar 2029
BayerBAY 3547926
anti-GPC3 antibody-drug conjugate with actinium-225 alpha emitter
GPC3Phase 1Hepatocellular CarcinomaJul 2029
Second Affiliated Hospital of Guangzhou Medical UniversityGPC3 and/or TGFβ targeting CAR-T cells
Engineered CAR-T cells targeting GPC3 and/or TGFβ with knockdown of PD1/HPK1, enhanced wit
GPC3, TGFB1Phase 1Hepatocellular CarcinomaAug 2029
RayzeBioRYZ801
GPC3-targeted alpha-emitting radiotherapeutic (Ac-225 conjugate)
GPC3Phase 1Hepatocellular Carcinoma (HCC)Jun 2030
Baylor College of MedicineAGAR T cells (GPC3-CAR T cells)
Glypican 3-specific chimeric antigen receptor T cells expressing interleukin-15
GPC3Phase 1Liver CancerAug 2040
Baylor College of MedicineCATCH T cells (GPC3-CAR T cells)
IL-15 armored glypican 3-specific chimeric antigen receptor T cells
GPC3Phase 1Liver Cell CarcinomaDec 2040
SOTIO BiotechBOXR1030
anti-GPC3 CAR-T cell therapy
GPC3Phase 1Hepatocellular CarcinomaDec 2042

Conditions

Hepatocellular Carcinoma (6) Hepatocellular Carcinoma (HCC) (2) Liver Cancer (2) Advanced Solid Tumor (1) Neoplasms (1) Advanced Hepatocellular Carcinoma (1) Advanced Malignancies (1) Liver Cell Carcinoma (1) Hepatoblastoma (1) Glioblastoma Multiforme of Brain (1) Primary Extra-cranial Solid Tumor (1) Advanced Hepatocellular Carcinoma (HCC) (1)

Modalities

other (8), small molecule (6), protein or peptide (2), mixed (2), antibody (1)

Companies

Baylor College of Medicine (3) Second Affiliated Hospital of Guangzhou Medical University (2) AstraZeneca (1) Keymed Biosciences Co.Ltd (1) Newish Technology (Beijing) (1) Aptamer Sciences (1) National Cancer Institute (NCI) (1) Zhejiang University (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Zymeworks BC (1) RayzeBio (1) SOTIO Biotech (1) Bayer (1) Memorial Sloan Kettering Cancer Center (1) Eastern Hepatobiliary Surgery Hospital (1) BeOne Medicines (1)

Related targets

TGFB1 (1) GPCS (1) PVRL4 (1) KLRC1 (1) TROP2 (1) B7H3 (1) MSLN (1) GUCY2C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.